• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名原发性闭经的青春期女性患大泌乳素瘤。

Macroprolactinoma in an adolescent female with primary amenorrhoea.

作者信息

Zhang Ning, White Eleanor, Weir Tessa, Dexter Mark, Varikatt Winny, Glastras Sarah J

出版信息

Endocrinol Diabetes Metab Case Rep. 2024 Dec 23;2024(4). doi: 10.1530/EDM-24-0033. Print 2024 Oct 1.

DOI:10.1530/EDM-24-0033
PMID:39713937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11737432/
Abstract

SUMMARY

Paediatric pituitary adenomas are rare in children and adolescents and differ from adults in both clinical presentation and management. We present the case of a 14-year-old female with primary amenorrhoea secondary to a macroprolactinoma, showing a modest radiological and biochemical response to dopamine agonist (DA) therapy. Despite a 10-month duration of increasing DA therapy, initial symptoms of primary amenorrhoea and hyperprolactinaemia persisted, with new symptoms of weight gain, lethargy and low mood. A transsphenoidal resection of the macroprolactinoma was successfully performed, followed by the initiation of additional hormonal therapy. This case explores the unique challenges of treating a macroprolactinoma refractory to medical management in adolescence.

LEARNING POINTS

Management of macroprolactinomas in childhood and adolescence can bring unique challenges, including a delay in sexual development, often presenting with primary or secondary amenorrhoea in girls.DA therapy is typically the first-line therapy in treating macroprolactinomas; however, resistance in paediatric and adolescent patients is associated with tumour size and initial prolactin levels.Surgical resection should be considered as a second-line therapy for adolescents unable to tolerate high-dose DA therapy or have inadequate response to DA therapy.There are a range of potential surgical complications, including permanent or transient diabetes insipidus, meningitis, cerebrospinal fluid leakage and hypopituitarism.Timely management of macroprolactinomas is important for secondary sex characteristics, bone development and psychological well-being.

摘要

摘要

小儿垂体腺瘤在儿童和青少年中较为罕见,其临床表现和治疗方法与成人不同。我们报告一例14岁女性,因大泌乳素瘤继发原发性闭经,对多巴胺激动剂(DA)治疗有适度的影像学和生化反应。尽管增加DA治疗长达10个月,但原发性闭经和高泌乳素血症的初始症状持续存在,还出现了体重增加、嗜睡和情绪低落等新症状。成功实施了经蝶窦大泌乳素瘤切除术,随后开始了额外的激素治疗。本病例探讨了治疗青春期对药物治疗难治的大泌乳素瘤所面临的独特挑战。

学习要点

儿童和青少年大泌乳素瘤的治疗可能带来独特挑战,包括性发育延迟,女孩常表现为原发性或继发性闭经。DA治疗通常是治疗大泌乳素瘤的一线疗法;然而,儿科和青少年患者的耐药性与肿瘤大小和初始泌乳素水平有关。对于无法耐受高剂量DA治疗或对DA治疗反应不佳的青少年,应考虑手术切除作为二线治疗。存在一系列潜在的手术并发症,包括永久性或暂时性尿崩症、脑膜炎、脑脊液漏和垂体功能减退。及时治疗大泌乳素瘤对第二性征、骨骼发育和心理健康很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/01e0d93cba5f/EDM-24-0033fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/79146e163023/EDM-24-0033fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/03e2e53dd1c9/EDM-24-0033fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/782d3f2a5f15/EDM-24-0033fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/01e0d93cba5f/EDM-24-0033fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/79146e163023/EDM-24-0033fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/03e2e53dd1c9/EDM-24-0033fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/782d3f2a5f15/EDM-24-0033fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e93/11737432/01e0d93cba5f/EDM-24-0033fig4.jpg

相似文献

1
Macroprolactinoma in an adolescent female with primary amenorrhoea.一名原发性闭经的青春期女性患大泌乳素瘤。
Endocrinol Diabetes Metab Case Rep. 2024 Dec 23;2024(4). doi: 10.1530/EDM-24-0033. Print 2024 Oct 1.
2
Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.催乳素瘤患者停用多巴胺激动剂治疗后催乳素血症复发很常见,尤其是在大腺瘤患者中。
Clin Endocrinol (Oxf). 2011 Dec;75(6):819-24. doi: 10.1111/j.1365-2265.2011.04136.x.
3
Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients.儿童和青少年的大泌乳素瘤:77例患者治疗反应的相关因素
J Clin Endocrinol Metab. 2015 Mar;100(3):1177-86. doi: 10.1210/jc.2014-3670. Epub 2014 Dec 22.
4
Multiple Endocrine Neoplasia Type 1 (MEN1) Presenting as an Invasive Macroprolactinoma Complicated by Acute Bacterial Meningitis.1型多发性内分泌腺瘤病(MEN1)表现为侵袭性大泌乳素瘤并并发急性细菌性脑膜炎。
Cureus. 2021 Dec 1;13(12):e20086. doi: 10.7759/cureus.20086. eCollection 2021 Dec.
5
Diagnosis and drug therapy of prolactinoma.泌乳素瘤的诊断与药物治疗
Drugs. 1996 Jun;51(6):954-65. doi: 10.2165/00003495-199651060-00004.
6
Meningitis as a presentation of macroprolactinoma.以脑膜炎为表现的大泌乳素瘤
Exp Clin Endocrinol Diabetes. 2009 Jul;117(7):361-4. doi: 10.1055/s-2007-1004553. Epub 2009 Jul 9.
7
Determinants of cerebrospinal fluid leakage in a large cohort of macroprolactinomas.一大群大泌乳素瘤患者脑脊液漏的决定因素
Ann Endocrinol (Paris). 2025 Apr;86(2):101685. doi: 10.1016/j.ando.2025.101685. Epub 2025 Jan 14.
8
Bacterial meningitis as a first presentation of pituitary macroprolactinoma.细菌性脑膜炎作为垂体大泌乳素瘤的首发表现。
Endocrinol Diabetes Metab Case Rep. 2014;2014:140028. doi: 10.1530/EDM-14-0028. Epub 2014 May 1.
9
Gender differences in macroprolactinomas: a single centre experience.男性和女性大泌乳素瘤的临床特征比较:单中心经验。
Endocr Connect. 2016 Jan;5(1):20-7. doi: 10.1530/EC-15-0105. Epub 2015 Dec 18.
10
Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.儿童和青少年催乳素瘤-发病时的肿瘤大小预测治疗策略:单中心系列及系统评价和荟萃分析。
Clin Endocrinol (Oxf). 2021 Mar;94(3):413-423. doi: 10.1111/cen.14394. Epub 2020 Dec 26.

本文引用的文献

1
Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.儿童和青少年垂体腺瘤的诊断和管理共识指南:第 2 部分,特定疾病。
Nat Rev Endocrinol. 2024 May;20(5):290-309. doi: 10.1038/s41574-023-00949-7. Epub 2024 Feb 9.
2
Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients.儿童及青少年垂体大腺瘤:7例临床分析
Clin Diabetes Endocrinol. 2023 Oct 31;9(1):5. doi: 10.1186/s40842-023-00153-6.
3
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
催乳素分泌型垂体腺瘤的诊断和治疗:垂体学会国际共识声明。
Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5.
4
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.肢端肥大症中生长抑素受体配体反应的预测因素:一项前瞻性研究。
J Clin Endocrinol Metab. 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512.
5
An Approach to the Patient With Delayed Puberty.青春期延迟患者的处理方法。
J Clin Endocrinol Metab. 2022 May 17;107(6):1739-1750. doi: 10.1210/clinem/dgac054.
6
Management of prolactinomas in children and adolescents; which factors define the response to treatment?儿童和青少年泌乳素瘤的管理;哪些因素决定了治疗反应?
Pituitary. 2022 Feb;25(1):167-179. doi: 10.1007/s11102-021-01184-x. Epub 2021 Sep 13.
7
First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.一线手术治疗泌乳素瘤:来自三级转诊中心长期随访研究的经验。
J Endocrinol Invest. 2021 Dec;44(12):2621-2633. doi: 10.1007/s40618-021-01569-6. Epub 2021 Apr 13.
8
Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.儿童和青少年催乳素瘤-发病时的肿瘤大小预测治疗策略:单中心系列及系统评价和荟萃分析。
Clin Endocrinol (Oxf). 2021 Mar;94(3):413-423. doi: 10.1111/cen.14394. Epub 2020 Dec 26.
9
Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.单中心儿童和青少年泌乳素瘤的临床、激素和神经影像学特征及治疗结果。
Front Endocrinol (Lausanne). 2020 Aug 4;11:527. doi: 10.3389/fendo.2020.00527. eCollection 2020.
10
Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: a brief review.青少年及年轻女性高催乳素血症的临床表现、评估与管理:简要综述
Acta Biomed. 2019 Jan 23;90(1):149-157. doi: 10.23750/abm.v90i1.8142.